Boehringer Ingelheim GmbH
http://www.boehringer-ingelheim.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Boehringer Ingelheim GmbH
Moderna Takes The Lead With Plan To Tackle New COVID-19 Variants
Moderna has unveiled plans to develop a new booster vaccine, tweaked to meet the threat posed by the South African strain.
Coronavirus Update: EU Demands AstraZeneca Meets Its Vaccines Commitments After Supply Warning
Plus Takeda starts vaccine trial in Japan and South Korea clears Celltrion's antibody therapeutic.
Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.
Scrip Asks…What Does 2021 Hold For Biopharma? Part 2: COVID-19 Shock Waves And Silver Linings
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- AMAL Therapeutics SA
- ICD Therapeutics
- SSP Co., Ltd.
- Vira Therapeutics GmbH (Vira T)